Comprehensive evaluation of deep and graph learning on drug–drug interactions prediction

X Lin, L Dai, Y Zhou, ZG Yu, W Zhang… - Briefings in …, 2023 - academic.oup.com
Recent advances and achievements of artificial intelligence (AI) as well as deep and graph
learning models have established their usefulness in biomedical applications, especially in …

[HTML][HTML] Data mining of the public version of the FDA Adverse Event Reporting System

T Sakaeda, A Tamon, K Kadoyama… - International journal of …, 2013 - ncbi.nlm.nih.gov
Abstract The US Food and Drug Administration (FDA) Adverse Event Reporting System
(FAERS, formerly AERS) is a database that contains information on adverse event and …

Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study

JE Salem, A Manouchehri, M Moey… - The Lancet …, 2018 - thelancet.com
Summary Background Immune checkpoint inhibitors (ICIs) have substantially improved
clinical outcomes in multiple cancer types and are increasingly being used in early disease …

Ibrutinib-mediated atrial fibrillation attributable to inhibition of C-terminal Src kinase

L Xiao, JE Salem, S Clauss, A Hanley, A Bapat… - Circulation, 2020 - Am Heart Assoc
Background: Ibrutinib is a Bruton tyrosine kinase inhibitor with remarkable efficacy against B-
cell cancers. Ibrutinib also increases the risk of atrial fibrillation (AF), which remains poorly …

Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study

DB Johnson, A Manouchehri, AM Haugh… - … for immunotherapy of …, 2019 - Springer
Background Immune checkpoint inhibitors (ICI) produce durable antitumor responses but
provoke autoimmune toxicities, including uncommon but potentially devastating neurologic …

Cardiovascular toxicities associated with ibrutinib

JE Salem, A Manouchehri, M Bretagne… - Journal of the American …, 2019 - jacc.org
Background: Ibrutinib has revolutionized treatment for several B-cell malignancies.
However, a recent clinical trial where ibrutinib was used in a front-line setting showed …

Frequency and associations of adverse reactions of COVID-19 vaccines reported to pharmacovigilance systems in the European Union and the United States

D Montano - Frontiers in public health, 2022 - frontiersin.org
Introduction This study aims to provide a risk assessment of the adverse reactions related to
the COVID-19 vaccines manufactured by AstraZeneca, Janssen, Moderna, and Pfizer …

Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database

C Zhou, S Peng, A Lin, A Jiang, Y Peng, T Gu… - …, 2023 - thelancet.com
Background With the increasing use of immune checkpoint inhibitors (ICIs) for tumour
immunotherapy, the immune-related adverse events (irAEs) caused by their collateral effect …

Quantitative signal detection using spontaneous ADR reporting

A Bate, SJW Evans - Pharmacoepidemiology and drug safety, 2009 - Wiley Online Library
Quantitative methods are increasingly used to analyse spontaneous reports. We describe
the core concepts behind the most common methods, the proportional reporting ratio (PRR) …

[HTML][HTML] Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database

JL Montastruc, A Sommet, H Bagheri… - British journal of …, 2011 - ncbi.nlm.nih.gov
The insufficiencies of basic (experimental) pharmacology as well as clinical trials for
studying ADRs are well known. Animal physiology often differs from that of humans. Clinical …